Cipla Partners With CSIR-CDRI To Advance Ophthalmic Antifungal Treatment Development

Mumbai: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that the company has entered into a collaborative research agreement with CSIR-Central Drug Research Institute (CSIR-CDRI), a constituent laboratory of the Council of Scientific and Industrial Research, Government of India, to jointly develop a novel ophthalmic formulation for fungal keratitis. The collaboration aims to leverage the combined expertise and resources of both organizations to develop a safe and efficacious drug for fungal keratitis.

Globally, approximately 1.2 million cases of fungal keratitis are reported every year with tropical countries recording a higher incidence. Fungal keratitis often occurs following ocular trauma and exposure to fungal pathogens from organic matter, thus putting agricultural workers at greater risk. Other risk factors include the use of local steroid eye drops, injury, poor personal hygiene, and regular contact lens wear. Left untreated, the condition can result in corneal destruction, leading to a profound loss of vision. Existing therapies have limitations, such as the need for prolonged and frequent use of drugs, and emerging drug resistance.

CSIR-CDRI has developed a prototype formulation for an antifungal drug to optimize its delivery in the eye. In preclinical studies, this formulation supports faster resolution of the infection. Cipla will scale up the product, conduct the required studies and seek regulatory approvals for commercialization, ensuring accessibility for those in need.

Commenting on this association Mr. Umang Vohra, Managing Director, and Global CEO, Cipla, said, “At Cipla, our growth is centered on our commitment to patients, extending care to communities through patient-centric innovation. This collaboration with CSIR-CDRI is a testament to our commitment to providing innovative and top-quality healthcare solutions to all those in need, encompassing drugs, devices, and diagnostics. With this, we are sustaining our antimicrobial resistance stewardship by investing in anti-infectives and leading industry voice in the fight against AMR.”

Welcoming this partnership, Dr Radha Rangarajan, Director CSIR-CDRI said, “Our research focuses on finding innovative, cost-effective solutions for India’s unmet clinical needs. CDRI scientists have developed a unique ophthalmic formulation of the antifungal drug. This in turn, is expected to accelerate cure and lead to better outcomes. Our collaboration with Cipla will enable the translation of the research into a drug product, with the potential to reduce the burden of disease.”

This research and development endeavor unites both Cipla and CSIR-CDRI in their commitment to affordable healthcare. The two partners have an ongoing collaboration for the development of Levormeloxifene for contraception.

Related Posts

  • Pharma
  • April 24, 2024
  • 43 views
Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines

Kathmandu: In a bid to ensure the quality of medicines being prescribed to patients, the Department of Drug Administration (DDA) has been preparing to carry out on-site tests of medicines. For…

  • Pharma
  • April 23, 2024
  • 30 views
‘Auric’ Relied On Amazon Reviews For Research Claims To Cure Fatty Liver

Ranchi : Patanjali’s case is going on in the Supreme Court for misleading people by showing misleading advertisements. But there are many other pharmaceutical companies in this category. In fact,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines

Nepal Drugs Regulator To Conduct On-Site Testing Of Medicines

‘Auric’ Relied On Amazon Reviews For Research Claims To Cure Fatty Liver

‘Auric’ Relied On Amazon Reviews For Research Claims To Cure Fatty Liver

Misleading Ads Case: Patanjali Issues Public Apology In A Daily Newspaper

Misleading Ads Case: Patanjali Issues Public Apology In A Daily Newspaper

AFMS Collaborates With IIT Delhi To Develop Medical Devices

AFMS Collaborates With IIT Delhi To Develop Medical Devices

Ayush Ministry Told To Act Against Firm Selling Medicine Named ‘Insulin’

Ayush Ministry Told To Act Against Firm Selling Medicine Named ‘Insulin’

2 Youths Arrested With 44770 Pregabalin Capsules

2 Youths Arrested With 44770 Pregabalin Capsules